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Abstract 
 
Stem cell delivery has shown promise in cardiac regeneration. One method of delivery is 
the use of human mesenchymal stem cells (hMSCs) seeded on biological microthreads. 
However, during delivery, the cells are often damaged due to exposure to shear stresses 
created by the heart wall. The purpose of this project was to design a protective sheath 
encompassing the threads to increase the number of cells successfully delivered. The 
team developed a sheath that can be easily manufactured as well as quickly assembled 
with the microthreads and suture needle. Additionally, the sheath possesses enough 
mechanical stability to withstand the forces placed on it during surgery. To accomplish 
this, the team selected several biomaterials based on literary research and then conducted 
various tests to determine the properties required of the biomaterial in order for it to 
protect the cell-loaded microthreads. This included establishing mechanical strength and 
delivery rates of the sheath. The team discovered that a protective sheath made from an 
electrospun variable form of polyethylene terephthalate (PET) provided sufficient 
mechanical stability to protect the hMSC-loaded microthreads during delivery to the 
heart. 
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Introduction 
The heart must be able to remain functional and pump blood to the lungs and the 
rest of the body in order to maintain life. However, as the population continues to age, 
complications from heart disease can cause serious health problems or death. Myocardial 
infarction (MI), or more commonly known as a heart attack, affects approximately 1.2 
million Americans each year. Five million Americans experience heart failure every year, 
which is estimated to contribute to 300,000 deaths (Berger, 2009). Myocardial infarction 
causes cell death within the heart wall, and if severe enough, MI can eventually lead to 
heart failure. This in turn, can sometimes require a heart transplant, but the demand for 
transplantable hearts is much higher than the available supply. Thus, there is great need 
for better treatment of heart disease and heart failure.  
Regenerative medicine and the use of stem cells are currently being explored in 
researchers’ applications for treating heart disease. Various types of stem cells exist, but 
it is embryonic, induced pluripotent, and human mesenchymal stem cells that hold the 
most potential in myocardial regeneration applications. Each of these three types of stem 
cells possesses advantages and disadvantages, but human mesenchymal stem cells are 
currently the most used because they have been shown to improve cardiac function (Fox, 
2009, Amado et al, 2005, and Pittenger, 2004).  
Scientists have been developing and testing stem cell delivery methods. However, 
many of these methods have limitations including a lack in site specificity and efficiency 
in delivering viable stem cells to the target region (Murphy, 2008). The most common 
delivery techniques being used today include intravenous injection, endocoronary 
infusion, intramyocardial injection, and implantable scaffolds.  
A new technique is also being developed involving the use of biodegradable 
microthreads. The stem cells are seeded on the microthreads, which are then sewn 
through the infarcted area of the heart. This allows for greater control of implantation and 
engraftment, providing the surgeon with the ability to precisely guide the microthreads to 
the exact location within the heart wall. Despite recent successes with delivering viable 
stem cells to the infarct, the fibrin microthread technique exposes the stem cells to shear 
stresses during implantation. This often results in removal or damaging of the stem cells. 
It is the purpose of this team to design, develop, and test a suitable form of 
protection for the cells seeded on the biodegradable microthreads. This design will reduce 
the shear stresses placed on the cells during implantation and in turn, increase the 
quantity and quality of viable cells to the infarcted area. 
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Background and Literature Review 
In this chapter we begin by introducing the general anatomy and pathology of the 
heart and the need for addressing heart complications such as myocardial infarction and 
heart failure. Second, we provide a review of regenerative medicine and stem cells, which 
currently are receiving great attention from the medical and scientific communities as 
solutions to these cardiac complications. We explore five methods presently used to 
deliver stem cells to damaged myocardium, and we investigate several biomaterials that 
hold potential for developing a method that better protects the cells during fibrin 
microthread delivery. We present this information in the following sections. 
 
The Heart 
The heart is a muscular organ responsible for pumping blood throughout the 
body. As a vital organ, the heart operates in conjunction with the circulatory system to 
provide oxygenated blood to other organs and supplying energy to power cellular 
processes. It is divided into four chambers: the left and right atria and the left and right 
ventricles. The atria receive the blood, whereas the ventricles pump the blood from the 
heart to different organs of the body completing the circulatory cycle (American Heart 
Association, 2003).  
The heart plays a vital role in maintaining a healthy life. However, certain 
complications can arise such as ischemia, blocked arteries, or arrhythmias, all of which 
can lead to serious health problems. 
 
Heart Failure and Myocardial Infarction 
Myocardial infarction occurs when blood flow from the blood vessels to the heart 
is blocked or impeded, thus interrupting the oxygen supply to the myocardium (Mayo 
Clinic, 2010). Consequently, the heart muscle dies. Heart failure is a condition in which 
the heart is unable to pump enough blood throughout the body (Berger, 2009). The 
leading cause of heart failure due to MI occurs when roughly 25% of the cardiomyocytes 
in the ventricle die (Murry, et al., 2006). When the blood is incapable of reaching other 
parts of the body, additional problems may arise such as congestion in the lungs, liver, 
gastrointestinal tract, and limbs. Insufficient blood flow leads to a lack of oxygen and 
nutrition, damaging the organs and reducing their ability to function properly. Each year, 
approximately 1.2 million Americans suffer from MI and about 5 million have heart 
failure contributing to an estimated 300,000 deaths (Berger, 2009). The estimated total 
cost of heart failure in the United States in 2008 was approximated to be more than $35 
billion (Cowie, 2000). On any given day, approximately 4,000 people are in need of a 
heart transplant (Mayo), but only 2,210 and 2,192 were performed in the United States in 
2007 and 2006, respectively (American Heart Association, 2009). Due to the increasing 
need for heart transplants as well as the limited supply of donors, only half of the patients 
in need actually receive transplants. Because of the large number of deaths each year due 
to heart failure and the limited amount of heart transplant donors, medical advancements 
are imperative. More specifically, researchers are continuously in search of new methods 
of cardiac regeneration.  
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Regenerative Medicine 
Regenerative medicine is a relatively new field of science involving the creation 
of functional and living tissues in order to address a wide range of medical issues. It helps 
natural processes work faster, as well as aids in the repair and re-growth of natural tissues 
and organs. It typically involves experimentation with stem cells, biomaterials, or the 
manipulation of cell-signaling. Regenerative medicine holds the potential for scientists to 
develop replacement organs for those in need of transplants as well as discovering new 
ways to address certain diseases (National Institutes of Health, 2009). 
 
Stem Cells 
Stem cells can be found all over the body, and they possess the ability to 
differentiate into new cell types. They are different from other cells in the body because 
they are unspecialized and can continually divide via cell division. Additionally, through 
the use of certain additives and precisely controlling their living environment, some stem 
cells can be manipulated into differentiating into a certain cell type (Fox, 2009).  
The ability of stem cells to regenerate into certain cells and tissues is very 
controversial within the scientific community, especially concerning adult stem cells. 
Some believe stem cells can undergo a process called transdifferentiation. This means a 
stem cell can turn into a cell that is entirely different from its previous state (Orlic, et al, 
2002). For example, a stem cell found in the brain might be believed to transdifferentiate 
into a skin cell. Others, however, claim that this process of transdifferentiation is 
impossible; they believe stem cells remain within their original cell lines (Murry, et al, 
2004). Yet another group of scientists believe stem cells do not differentiate at all; they 
believe stem cells secrete growth factors which direct other nearby cells to grow, 
replicate, and repair (Lee and Makkar, 2004). Additionally, stem cells can be categorized 
by their potency levels. Some stem cells are pluripotent, meaning they can become any 
type of cell within the body; these are typically called embryonic stem cells (ESCs). 
Multipotent stem cells are unable to participate in transdifferentiation, which most 
scientists term ―adult stem cells.‖ Unipotent stem cells simply self-renew themselves and 
have already differentiated into their specific cell-type. Both of these cell types are 
considered to have ―limited differentiation‖ capabilities because they can only specialize 
into certain cell types (National Institutes of Health, 2009). 
Embryonic, induced pluripotent, and mesenchymal stem cells are the primary 
three types of stem cells with prior success in cardiac regeneration. 
Embryonic Stem Cells 
Embryonic stem cells are pluripotent, giving them high potential in regenerative 
medicine and various medical applications. Not only have they been shown to 
differentiate successfully into cardiomyocytes, but once differentiated, embryonic stem 
cells have been shown to express heart proteins, possess myofibrillar organization, and 
the ability to contract (Schuldt, et al., 2008). However, using ESCs requires scientists to 
destroy blastocysts, which is where this type of stem cell is located; consequently, many 
people object to using ESCs because of the ethical, religious, and political controversies 
associated with them. Additionally, while ESCs’ high potency provides them with the 
ability to become any type of cell, it unfortunately also makes them more likely to 
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proliferate uncontrollably and lead to the formation of teratomas (National Institutes of 
Health, 2009). 
Induced Pluripotent Stem Cells  
Another type of stem cell with potential for myocardial regeneration is induced 
pluripotent stem cells (IPSCs). They were developed in 2007 when, Shinya Yamanaka, a 
doctor in Japan turned regular adult cells back into embryonic stem cells. Embryos were 
not used in this process, thus avoiding the embryonic stem cell controversy. To create 
these IPSCs, Yamanaka located the gene switches responsible for programming human 
skin stem cells, and he turned those same switches on in the adult skin cells. This caused 
the skin stem cells to turn back to their pre-differentiated status as embryonic stem cells. 
With years of experimentation, Yamanaka discovered the four genes responsible for 
reverting differentiated cells back to an embryonic, pluripotent state. Problems, however, 
began to surface as further research was conducted on these new stem cells. One of the 
four genes Yamanaka identified was an oncogene. Therefore, when the IPSCs were 
placed within mice, cancerous growths began to form (Fox, 2009). Additional research is 
being done to eliminate the need for the oncogene in producing IPSCs; however, 
achieving successful implantation of these cells without triggering the formation of 
tumors currently requires further research and experimentation. 
Human Mesenchymal Stem Cells 
Human mesenchymal stem cells (hMSCs) are derived from bone marrow and are 
able to differentiate into different types of cells including fat, cartilage, and bone. Many 
studies have been conducted to determine whether or not hMSCs can also differentiate 
into cardiomyocytes, or heart muscle cells. Despite this research, the actual mechanism 
by which hMSCs operate and help to restore heart function still remains controversial. 
Some believe the cells simply generate new myocardium through either 
transdifferentiation, fusion with existing living cardiomyocytes, or secretion of growth 
factors (Lee and Makkar, 2004). Others believe the hMSCs help release myocardial wall 
tension at the area of infarct, thereby allowing the heart to more easily contract (Luciano, 
2006). Either way, the studies show that implantation of hMSCs to damaged heart tissue 
helps increase heart functionality. Additionally, using hMSCs in cardiac regeneration 
applications does not require the patient to take immunosuppressant drugs because the 
stem cells come directly from the patient. hMSCs have also been shown to increase 
angiogenesis, or the growth of capillaries, which helps increase blood flow around the 
heart and supports myocardial regeneration efforts (Steinhoff, 2009). hMSCs, therefore, 
hold much promise in the field of cardiac regeneration.  
 
Delivery Methods 
Currently there are several accepted delivery techniques for stem cells to infarcted 
areas of the heart. They are intravenous injection, intracoronary infusion, intramyocardial 
injection, and scaffold implantation. A new approach to scaffold delivery is biological 
microthreads. 
Intravenous Injection 
Intravenous injection (IV) is a technique using a suspension of stem cells that is 
directly injected into a vein of the subject. This allows the cells to circulate throughout 
the heart and the rest of the body. This method has been of particular interest because IV 
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is minimally invasive when compared with other methods currently used and/or 
investigated (Wolf, et al, 2009). Studies have demonstrated that hMSCs delivered 
through intravenous delivery migrate to the injured target site of the heart (Pittenger, et 
al, 2004). However, other studies have observed a large majority of the cells never 
reaching the heart infarct. Immediately following injection, cells are often trapped in the 
lungs, which can lead to severe lung damage (Fischer, et al, 2008). While some of the 
stem cells do in fact reach their intended target site, others are often found migrating to 
other filtering organs including the liver, spleen, and kidneys (Fischer, et al, 2008). 
Within the first hour of injection 50-60 % are caught in the lungs, four hours later 42% in 
the spleen, 21% in the liver and only 6% in the lungs (Fischer, et al, 2008). This lack of 
site localization is the major drawback of intravenous injection. Acknowledging this 
distinct disadvantage, researchers have hypothesized that although the majority of the 
delivered cells are trapped in the lungs, the hMSCs secrete TSG-6, an anti-inflammatory 
protein, which results in a decreased infarct size (Lee, et al, 2009). In spite of this, there is 
a major concern with this method in which hMSCs have the potential to continue to 
differentiate and proliferate. A low percentage of the stem cells reach the infarcted region 
of the heart, while a high percentage of them are distributed throughout the body, causing 
potential for abnormal growths to occur in any area of the body where the cells are 
trapped (Freyman, et al, 2006). Since it is difficult to track the migration and location of 
the delivered cells, tumors may develop in areas where they are least expected. Therefore, 
despite the fact that this method is minimally invasive, IV carries many risks and 
disadvantages. 
Intracoronary Infusion 
The second method of stem cell delivery to the heart, intracoronary infusion 
utilizes a stoppage of blood flow in order to engraft stem cells (Perin, et al, 2008). This 
requires the use of an angioplasty balloon in order to successfully engraft the stem cells. 
This angioplasty balloon is inserted in a coronary artery upstream of the infarct and 
inflated, which stops arterial blood flow. A solution containing the stem cells is then 
infused behind the inflated balloon. After two minutes, blood flow is restored to the 
coronary artery by deflating the balloon. This process is repeated multiple times until the 
entire solution of stem cells is delivered (Freyman, et al, 2006). Although intracoronary 
infusion is more site-specific than the intravenous injection technique, a majority of the 
cells get distributed throughout the body away from the intended target site. This is 
shown with an engraftment rate of approximately 3%. Furthermore, after one to two 
hours of injection, stem cell retention rate ranged between 1.3% and 5.3% (Laflamme and 
Murry, 2005). This is due to the huge influx of blood when the balloon is deflated, 
causing the stem cells to be washed away. Intracoronary infusion has also been shown to 
decrease arterial blood flow, which can lead to further myocardial damage (Freyman, et 
al, 2006). Cells that were found to attach to the myocardium were localized around the 
edge of the infarct or area of healing. Cells were absent from the center of the injury site, 
showing low cell survival in the ischemic area of the heart (Perin, et al, 2008)  
Intramyocardial Injection 
Another method of stem cell delivery is intramyocardial injection. This technique 
utilizes multiple direct injections of a stem cell suspension into and around the infarct. 
Studies have shown that this is a practicable method of delivery, and complications have 
yet to be observed other than some stem cells leaking through the injection track when 
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the heart contracts. Furthermore, these studies have hint to researchers that improved 
myocardial contractions occur post injection (Laflamme and Murry, 2005). It is the most 
localized injected delivery method because the stem cells do not migrate as far away from 
the injection site as the intravenous injection and intracoronary infusion techniques 
(Freyman, et al, 2006). With intramyocardial injection however, the stem cells are found 
to migrate within the tissue and do not remain at the specific intended target site because 
some travel back out of the injection tract as the heart contracts. 
Scaffold 
The fourth method of stem cell delivery used in myocardial regeneration efforts 
involves using a scaffold or a cardiac patch. The implantation of a scaffold replaces or 
covers infarcted tissue with a tissue engineered graft. This graft acts like a template for 
the newly transplanted cells (Alperin, et al., 2005). Stem cells are seeded on the scaffold, 
which can be made of a variety of biodegradable biomaterials. That material, from which 
the scaffold is made, however, must be able to support cardiac function, survive the 
ischemic period after the infarct, and withstand the demanding mechanical properties of 
the heart. For example, some patches are constructed of natural type I collagen, synthetic 
polymers such as PLGA or polyurethane, or composites of both natural and synthetic 
materials (Alperin, et al., 2005). This method allows for the stem cells to be implanted 
directly and uniformly on the site of the infarct, leading to higher engraftment rates. 
Previous studies have shown engraftment rates of approximately 23% (Simpson, et al., 
2007). In another study, few to no stem cells were found to have migrated to other organs 
(Park, et al., 2005). However, the seeding of a scaffold requires significant incubation 
time and access to a bioreactor. Another complication with the scaffold is the need for an 
invasive procedure to suture the patch onto the infarct area (Park, et al., 2005). 
Biodegradable Microthreads 
Thread-like scaffolds are used to imitate the fundamental fibrous structural 
elements found in native tissues such as tendon, ligament, and dermis. Fibrin is a natural 
biomaterial used for creating biopolymer microthreads. It contains cell-signaling 
properties that arbitrate the initial phase of tissue regeneration by promoting cell 
migration, attachment, and proliferation from the wound margin. It comes from a 
combination of fibrinogen and thrombin. The biodegradable microthreads can be 
produced from a mixture of bovine fibrinogen and bovine thrombin with the presence of 
calcium under a constant flow, allowing the thrombin to cleave a peptide on the 
fibrinogen molecule to facilitate fibrin polymerization and thread formation. This method 
is a novel technique for tissue regeneration. However, it is unknown whether or not this 
material provides both sufficient mechanical integrity and biodegradation for new tissue 
in-growth (Pins and Cornwell, 2007). 
Fibrin can be used to prevent blood loss, promote granulation tissue formation as 
a guide for the migration and proliferation of fibroblasts, and work as a sponge for 
cytokines and growth factors. Fibrin has the ability to promote repopulation and 
regeneration, as well as a high binding affinity for cytokines, growth factors, proteases 
and protease inhibitors, which promote key cell functions for wound healing. All 
together, fibrin, growth factors, and other bioactive molecules act to promote cellular 
infiltration and remodeling to ultimately regenerate tissue (Cornwell, 2007). 
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Fibrin is a novel biopolymer and a natural structural protein of healing tissues. It 
can be made from autologous materials, and fibrinogen can be isolated from a patient’s 
own blood, ensuring no immunological rejection.  
However, fibrin has a limited initial mechanical strength for high load bearing 
situations. When used in vitro, the mechanical integrity and strength properties are 
dependent upon the initial concentration of fibrinogen (Cornwell, 2007). 
Biodegradable microthreads aligned in bundles significantly aid in tissue 
regeneration. hMSCs can be seeded on these microthreads, which have been tested in 
various experiments to confirm that the hMSCs remained viable, were still able to 
proliferate, and maintained their ability to differentiate (Murphy, 2008). 
Currently, biodegradable microthreads attached to a surgical needle are being 
used because this assembly mimics the common surgical procedure of placing a suture 
into a patient. This allows the surgeon to use a familiar technique without needing to be 
retrained. Biodegradable microthreads, with less than a 100μm diameter each, provide 
contact guidance, alignment, and orientation of the seeded cells (Cornwell, 2007). The 
needle-thread combination and small size of the threads also allows the surgeon to 
precisely place the hMSCs in the exact location of the infarct. Additionally, the 
biodegradable microthreads support all hMSC mechanisms, whether it is paracrine 
signaling or differentiation or transdifferentiation (Murphy, 2008). 
In Table 1, the engraftment rates from studies conducted using various animal 
models are summarized. 
 
Table 1: Engraftment Rates from Studies Conducted Using Various Animal Models (DiTroia, et al., 2008) 
Delivery Method Engraftment Percentage 
Intravenous injection 3% 
Intracoronary infusion 6% 
Intramyocardial injection 12% 
Scaffold 23% 
Biodegradable microthreads 65-70% 
 
Potential Biomaterials 
This section explores potential biomaterials from which the protective sheath can 
be made.  
Polyurethane 
Polyurethane is a segmented polymer with alternating hard segments and soft 
segments. Each polyurethane molecule consists of a macrodiol (or polyol) or backbone, a 
diisocyanate, and a chain extender (Tatai, et al, 2007). The backbone of polyurethane is 
the short segment, and it provides the polymer with flexibility. Both the diisocyanate and 
the chain extender are part of the hard segment. They contribute to the polymer’s 
strength, and they act as crosslinking elements (Wright, 2006).  
The ability to tailor polyurethane to exact specifics is a great advantage. By 
changing the chemicals and the ratio between soft segments and hard segments, it is 
possible to manipulate the physical and chemical properties of this polymer. 
Additionally, polyurethane is biodegradable, however, it can take weeks or years 
depending on how it was manipulated (Tatai, et al, 2007).  
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There are two main types of polyurethanes based on their structures, and the basic 
molecule of polyurethane can be seen in Figure 1. The first type is an aromatic 
polyurethane, which contains benzene rings. This gives the polymer high tensile strength 
and strong chemical resistance. The second type, aliphatic polyurethane, has a backbone 
consisting of a hydrocarbon. Because of this, aliphatic polymers are more flexible than 
other polyurethanes (Wright, 2006).  
 
Figure 1: Polyurethane Molecule (Tatai, et al., 2007) 
Medical grade polyurethane was first purposed as a biomaterial in 1967 (Boretos, 
Pierce, 1967). It is chosen in many applications because of its mechanical properties, 
blood compatibility and tailorability. It has been used in blood bags, heart valves, and 
vascular grafts (Kanyanta and Ivankovic, 2009). 
Polytetrafluoroethylene (PTFE) 
Polytetrafluoroethylene (PTFE), also known as Teflon, is a polymer with 
repeating CF2-CF2 chains as shown in Figure 2.  
 
Figure 2: Chemical Structure of PTFE (Lenntech, 2009) 
PTFE holds extraordinary characteristics that make it the ideal choice for a variety 
of products and applications. PTFE has one of the lowest coefficients of friction 
compared to any other material (Plastomer Technologies, 2009). It is abrasion resistant, 
meaning it is adaptable to harsh environments, flame resistant with a high melting point, 
and chemically inert and pure (Plastomer Technologies, 2009). It is also resistant to many 
chemicals, corrosion, weather, UV, and adherence (Lenntech, 2009). PTFE possesses 
great dielectric properties as well. This means that PTFE, as an insulating material, can 
withstand high voltages before it breaks down (Lenntech, 2009). PTFE is serviceable 
over a wide range of temperatures without a significant change in its physical 
characteristics or mechanical properties (Faughnan, et al., 1998). Table 2 lists a variety of 
PTFE’s properties. 
 
Table 2: List of Properties for PTFE (Plastomer Technologies, 2009) 
Property Units 
Virgin 
PTFE 
Reprocessed  
PTFE 
25% Glass  
PTFE 
Specific Gravity N/A 2.14-2.20 2.15-2.20 220-230 
Tensile Strength PSI 1500-3500 1500-2400 2000-3000 
Elongation % 250-350 75-200 100-260 
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Hardness Durometer "D" 50-60 N/A 55-65 
Water Absorption % 0.001 N/A 0.013 
Coeff. of Friction (Static) N/A 0.04 N/A 0.085 
Dielectric Constant N/A 2.00 2.26 2.4 
Dielectric Strength Volts 1000 450 235 
Coeff. of Thermal Expansion In./In./Ft. 5.5 x 10.3 N/A 2.75 x 10.3 
Coeff. of Thermal Conductivity Btu/hr/ftz 1.7 N/A 3.12  
PTFE has a long service life, retaining its properties over a long period of time, 
even when exposed to extreme temperatures, UV light and oils, oxidizing agents and 
solvents, or in water (Plastomer Technologies, 2009). In previous studies, PTFE has been 
used as a graft material for ophthalmic plastic surgery (Karesh, 1987). In this study, 
PTFE was found to be a non-antigenic, autoclavable, inert polymer that can be 
incorporated into surrounding tissue through fibrous ingrowth (Karesh, 1987).  
PTFE is widely used in many different applications. These include resins, 
additives, coatings, and films (Lenntech, 2009). The most common market application is 
a non-stick coating for cookware (Dupont Teflon). PTFE is also applied to a variety of 
different industries such as semiconductor, medical, chemical, automotive, electrical, 
aerospace, filtration, wire and cable, and petrochemical (Plastomer Technologies, 2009). 
More specifically, PTFE is used in labs for piping, tubing, and different containers. For 
example, PTFE tubing has been used for preconcentration techniques to determine 
specific levels of different chemicals in water samples (Som-Aum, 2002). Likewise, 
PTFE has been used in another study as a filter tube for a similar preconcentration 
procedure to analyze trace elements in an aqueous sample (Murakami, 2006).  
Polyethylene terephthalate (PET) 
Polyethylene terephthalate (PET) is a non-degradable thermoplastic polymer most 
commonly found in packaging materials. It is used in the packaging of foods, beverages, 
drugs, and cosmetics (Limam, et al., 2005). Its wide variety of use in these applications is 
due to its favorable physical, mechanical, and chemical properties. It is highly resistant to 
chemicals, impermeable to gas and water vapor, transparent, very resistant to fatigue, and 
can be made into films or fibers. Additionally, it is very light in weight, has a high 
melting point, and is resistant to creasing (Ceretti, et al., 2009 and Yang, et al., 2009).  
Made from terephthalic acid and ethylene glycol, PET has been found to 
contaminate the contents of its containers due to the migration of plasticizers. These 
plasticizers are esters of phthalic acid, which are added to PET to increase its flexibility. 
Because they are not covalently bonded to the PET, they are easily released into the 
container’s contents, and they have been linked to testicular and liver damage, liver 
cancer, and have formed teratomas in rodent models. 
Despite these complications, PET has been explored as a biomaterial in 
biocompatible, hemocompatible, antimicrobial surfaces, textiles, heart valve sewing 
rings, and vascular tissue engineering applications (Goddard, et al., 2007). For example, 
it has also been used in passive diastolic restraining (Chen, et al., 2008). Furthermore, 
experimentation with surface modifications to PET has helped to increase its poor 
wettability and adhesive properties (Yang, et al., 2009).  
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One study observed the effects of gamma sterilization on meshes made from PET 
and compared them to those made from polypropylene that underwent the same 
sterilization procedure. Through the use of various microscopy techniques, it was 
observed that the PET remained undamaged while the polypropylene meshes experienced 
significant damage. This study demonstrates that devices made from PET are easily 
sterilized and do not undergo any physical changes when being sterilized (Bracco, et al., 
2005). 
 
Potential Sheath Production Techniques 
This section explores the various methods by which fibers can be made from 
polymers. The first method explained is electrospinning, followed by injection molding 
and extrusion. 
Electrospinning 
The process of electrospinning involves using high voltages and jet stream of the 
desired polymer to make fibers. The fibers’ diameter can range anywhere between 1nm 
and 1μm depending on the polymer being used and the voltage. The process is generally 
cost effective; however, inexperienced technicians may experience difficulty in 
maintaining a stable and constant jet stream of polymer (Ramakrishna, et al., 2005). 
Figure 3 depicts a schematic of the components involved in electrospinning and how they 
work together. 
 
Figure 3: Process of Electrospinning (Ramakrishna, et al., 2005) 
The polymer is placed in solution form within a syringe (A) with a metal needle. 
This needle (B) is connected to a voltage supply (C). As the polymer is ejected from the 
syringe chamber and out of the needle, the combination of force and voltage creates 
fibers (D) that can be collected on a target (E) (Ramakrishna, et al., 2005). 
Injection Molding 
The process of injection molding is the most common polymer molding technique 
which accounts for 33% or all plastics production. The process is mainly made for large 
scale production. However they main fault of injection molding is plastics will deform 
during the cooling process especially with thin wall plastics (Chen, Turng, 2005). This 
process can be seen in Figure 4. 
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Figure 4: Process of Injection Molding (Strong, 2000) 
 
The process starts by loading the thermoplastic pellets into the hopper (A). The 
pellets are fed and melted together (B) by the screw. The liquid plastic then comes to the 
nozzle (C). Finally it enters the mold (D) (Strong, 2000). 
Extrusion 
Extrusion is a process in which materials are subjected to a specific cross-
sectional profile. The material is drawn through a die of a fixed cross-section as seen in 
Figure 5. The advantages of this method are its ability to create complex cross-sections 
for different applications, and also its ability to work with brittle materials, since the 
material only undergoes compressive and shear stresses. Common extruded materials are 
metals, polymers, ceramics and concrete. 
 
Figure 5: Extrusion Process (Pins and Cornwell, 2007) 
In previous studies, extrusion has been applied to produce structures of specific 
diameter and length. In relation to this project, solutions of fibrinogen and thrombin have 
been combined to form fibrin, and then coextruded at a specific rate through polyethylene 
tubing to create the thread-like structure as shown in Figure 5 (Cornwell, K, 2007). 
Within five minutes, the threads form at the bottom of the bath. This is a continuous 
procedure, capable of producing an indefinitely long material, depending on the length of 
the thread needed. Therefore, this process is proven to be efficient and capable of 
producing intricate structures for different applications.  
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Project Approach 
The following sections present the project hypotheses, assumptions, and goals.  
 
Project Hypotheses 
Hypothesis 1: The addition of a protective sheath will protect seeded hMSCs thereby 
increasing the number of viable cells available for cardiac regeneration. 
Rationale: When pulled through the heart, cells are subjected to shear stresses 
that can damage them or sever them from the fibrin microthread delivery vehicle.  
Specific Aim: Design a protective sheath that prevents shear stresses from 
damaging or severing seeded hMSCs from the biodegradable microthreads. 
Hypothesis 2: The addition of a protective sheath will increase the mechanical integrity 
of the biodegradable microthreads. 
Rationale: The current microthread delivery technique includes threads of 
collagen as well as fibrin. The collagen provides mechanical integrity, however, 
collagen increases thread diameter, but does not enhance the number of seeded 
cells. Therefore, no collagen threads and the addition of more biodegradable 
microthreads will increase the number of hMSCs that are  actually seeded on the 
threads. A protective sheath will provide the lost mechanical support due to the 
lack of collagen in the microthread bundle. 
Specific Aim: Design a protective sheath that increases the mechanical integrity 
of the biodegradable microthreads 
 
Project Assumptions 
To develop a working prototype of our design, specific project assumptions were 
established. 
 
Assumption 1: It is assumed that hMSCs will successfully encourage cardiac 
 regeneration when delivered to an infarcted region of the heart. 
Assumption 2: It is assumed that fibrin is the best material for the adhesion of hMSCs 
 and microthread delivery. 
Assumption 3: It is assumed that the microthread delivery technique is the preferred 
 method of stem cell delivery. 
Assumption 4: It is assumed that the preferred cell-seeding technique is dynamic 
 rotational seeding on bundle microthreads. 
 
Project Goals 
The goal of this project is to design a protective sheath for microthread stem cell 
delivery to the heart. To accomplish this goal, the following specific aims were 
developed. 
 Design a protective sheath that prevents shear stresses from damaging or severing 
 seeded hMSCs from the biodegradable microthreads, and 
 Design a protective sheath that increases the mechanical integrity of the fibrin 
 microthreads by exploring different mechanical properties of different 
 materials. 
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Product Design 
This chapter discusses the primary attributes that must be met in order for the 
device to be considered successful. The objectives, functions, constraints, and 
specifications helped create a more detailed and thorough client statement. Once the 
client statement was extensively revised, design alternatives were generated. 
 
Objectives, Functions, Specifications, and Constraints 
From the initial client statement and extensive research, design functions, 
objectives, specifications, and constraints were developed for creating a technology to 
address the problems with the current treatment options for breast cancer. 
Objectives 
To establish the following design objectives, the question ―What must the device 
be?‖ was answered. 
Objective #1: The device must be user-friendly. 
The final device would not be commercially viable without the first objective. 
The sheath must be easy to use by the client, and therefore easily inserted into the 
heart. It must be easily applied to the needle as well as easily sterilized prior to 
implantation. It must also be reliable, in which no complications arise during the 
attachment of the sheath to the needle or during surgery. Finally, the sheath must 
possess the ability to be easily altered for use with a smaller needle both in 
diameter and length.  
Objective #2: The device must be inexpensive. 
For manufacturing purposes, the sheath must be inexpensive. 
Objective #3: The device must be storable. 
The sheath must be storable in order for it to be easily transported and stocked in 
different laboratory settings. 
Objective #4: The device must be compatible. 
The protective sheath design must be safe for the technician to assemble, to 
handle, and to use. The device must also be compatible with the attached 
materials, such as the biodegradable microthreads and the needle. Additionally, 
the sheath must be easily integrated into the current procedures without requiring 
disruption of the flow of the surgery. Most importantly, the sheath must be safe 
for the patient, and in that respect, the sheath must cause minimal inflammatory 
response, minimal necrosis to the surrounding cells and tissues, and minimal 
damage to the heart wall during delivery.  
Objective #5: The device must be degradable or easily removable. 
Once the protective sheath has successfully been implanted in the heart wall the 
sheath must either degrade or be removed. If the sheath is degradable it must 
break down within a specific time and not have any harmful byproducts. If the 
sheath is to be removed the sheath must not damage the cells as it slides past the 
cells. 
Objective #6: The device should be multi-functional. 
The sheath must not only protect the hMSCs from the shear forces during 
implantation, but it must also be able to incubate the stem cells.  
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Objective #7: The device must be mechanically sound and durable.  
The sheath must be mechanically superior compared to the existing properties of 
the fibrin collagen bundles which have a UTS of 0.13N-0.14N. An acceptable 
factor of safety would be greater than two. The sheath must be durable so repeat 
use will not cause failure.  
Functions 
To establish the following design functions, the question ―What must the device 
do?‖ was answered. 
Function #1: The device must deliver the hMSCs to the target site.  
Function #2: The device must protect the hMSCs during delivery. 
Function #3: The device must contain the hMSCs during pre-surgery procedures 
 and during delivery. 
Function #4: The device must provide mechanical stability. 
Function #5: The device must either degrade or be removable. 
Function #6: The device must incubate the cells during pre-surgery procedures. 
Constraints 
The following design constraints were established. If the device did not meet 
these constraints, the device would have failed. 
Sheath Size 
The sheath must be able to contain 0.5-0.6mm bundle (without collagen). 
The sheath’s outer diameter must be less than 1mm. 
The sheath must be able to hold a minimum of 8 fibrin threads within it. 
Percentage of Engrafted Cells 
40% or more cells must be successfully engrafted (40% of 8,000 cells). 
Budget 
The total budget for the creation of this device is $468. 
Time 
This device must be completed before April 22, 2009. 
Specifications 
The following design specifications were developed in order to make this device 
function. 
 8,000 viable cells must be loaded on the thread 
 Greater than 40% engraftment of delivered cells 
 User interface time (time needed to assemble sheath with rest of apparatus) must 
 add no  more than 30min/bundle 
 Total time of making sheath must take less than 24hours 
 Greater than 50% of the cells must remain viable after delivery 
 Greater than 90% of the cells must be contained/remain on the thread after sheath 
 placement 
 Cells must remain viable when contained within the sheath for (x) amount of time 
 Must have 10-20N failure load (Fakharzadeh, 2009) 
 If to be degradable, it must fully degrade within one day and minimize negative 
 response 
 If to be removable, greater than 50% of the cells must remain viable once sheath 
 is removed 
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Client Statements 
Initial Client Statement: Design a method to protect cells seeded on biodegradable 
microthreads delivered to the heart. 
 
Revised Client Statement: Design a protective sheath to guard human mesenchymal 
stem cells seeded on biodegradable microthreads delivered to the heart. The sheath must 
be removable or degradable without causing any negative response. It must be user-
friendly, biocompatible, easily sterilized, transportable, and scalable that will be no larger 
than 1mm in diameter to fully encompass a 0.5-0.6mm bundle of microthreads. The 
sheath must also successfully deliver 40% or more of the stem cells seeded on the 
microthreads through the heart wall to the tissue without damaging or shearing off the 
hMSCs. 
 
Conceptual Designs 
The following section includes the six design alternatives developed during the 
course of several brainstorming sessions and in combination with what was learned from 
the literature 
Design Concept 1: Cone  
The cone conceptual design would use a hard metal or a polymer hollow cone. 
The needle would go from the base of the cone out through the tip of the cone as shown 
in Figure 6. 
 
Figure 6: Cone Design Concept 
 
The needle would then be held in place with the threads dangling out the base of 
the hollow cone with approximately 1cm of the cone overshadowing the microthreads. 
When the needle and cone are sewn through the heart, the cone would act like a wedge. 
By spreading the heart tissue away, a track would be created through which the 
microthreads would follow. Once the needle and the cone have passed through the heart 
wall, the cone can be removed, which would allow for the threads to be cut from the 
needle. 
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Design Concept 2: Stent  
The stent conceptual design was developed from the concept of a cardiovascular 
stent. However, this design would be made of a solid material instead of the typical wire 
braided mesh construction of a typical stent. At the top of the stent where the needle is 
attached, a hole in the sheath would allow for the surgeon to cut the threads from the 
needle after the device had been drawn through the heart tissue. A pull tab, attached at the 
opposite end, would allow the surgeon to easily grip and remove the entire sheath. These 
features of the stent conceptual design can be seen in Figure 7. 
 
Figure 7: Stent Design Concept 
Design Concept 3: Bandage 
This conceptual design would utilize a flat thin polymer sheet. A thin line of glue 
at the top edge of the top right corner would run down the right side of the sheet. To 
protect the threads, the needle would be placed on the glue at the top left corner. The 
needle would be oriented so that the tip and half of the needle would lie outside the sheet 
while the needle eye and microthreads would lie on the sheet. The sheet, the needle, and 
the threads would then be rolled up, creating a tube around the threads. The glue on the 
right side would then seal the tube. A cutting line would show the surgeon how far to pull 
the needle through the heart wall and where to cut the needle from the threads. This 
design alternative can be seen in Figure 8. 
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Figure 8: Bandage Design Concept 
The tube could be either biodegradable or could be removed. To remove the tube, 
it can be pulled out one end while the surgeon holds the thread at the other end.  
 Design Concept 3: Blanket 
The cape design would use a square thin flat sheet as can be seen in Figure 9. The 
needle would go through the center of the square and the threads dangling below. When 
sewn through the heart the sheet would collapse around the threads protecting them. The 
cape, needle and threads will be cut once the needle is through the heart wall. The cape 
could be biodegradable or removable. The cape would continue through the heart while 
the threads would be held in place. 
 
Figure 9: Blanket Design Concept 
Design Additions 
Small pull tabs can be attached to the sheath or to the threads. This would aid the 
surgeon in gripping the thread or the sheath allowing for more control. It would also act 
as a stopper for the threads. When a sheath is being removed the pull tab would give the 
surgeon a better grip making it easy to pull out the sheath. Any combination of the 
pervious designs could be used in the final design. For example the cones, tube with a 
pull tab.  
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Evaluation of Design Alternatives 
In order to determine which design concept would work best for protecting 
hMSCs during microthread delivery to the heart, a matrix was developed to compare all 
four design concepts. However, before this comparative matrix was used, a pairwise 
comparison chart, completed by the design team, the client, and the user were filled out 
as can be seen in Appendices F, G, and H. A blank pairwise comparison chart is show in 
Table 3 on the next page.
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Table 3: Blank Pairwise Comparison Chart 
 
User-
friendly 
Compatible Inexpensive Storable 
Degradable or easily 
removable 
Multi-
functional 
Mechanical 
integrity or 
durability 
Total 
User-friendly X        
Compatible  X       
Inexpensive   X      
Storability    X     
Degradable or 
easily removable 
    X    
Multi-functional      X   
Mechanical 
integrity and 
durability 
      X  
Once the pairwise comparison charts were completed and compiled, the design concept comparative matrix was then 
completed as shown in Table 4. All constraints had to be met by each design, otherwise it was not considered. The objectives, in 
weighted order, were listed, and each design was ranked on how well it would accomplish each individual objective. 
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Table 4: Design Concept Comparative Matrix 
 Conceptual Designs 
Cone Stent Bandage Blanket 
Constraints 
Contain 0.5-0.6mm bundle √ √ √ √ 
Sheath outer diameter 
<1mm 
√ √ √ √ 
Minimum 8 fibrin threads fit 
inside 
√ √ √ √ 
40% of 8,000 cells 
successfully engrafted 
√ √ √ √ 
Budget: $468 √ √ √ √ 
Completed by April 22
nd
 √ √ √ √ 
Objectives 
Value per Weighted 
Objective 
 
7 
√’s 
Compatible 
√√√√√√√ √√√√√√√ √√√√√√√ √√√√√√√ 
6 
√’s 
Mechanical integrity 
√√√√√√ √√√√√√ -- -- 
5 
√’s 
Degradable/Removable 
-- √√√√√ √√√√√ -- 
4 
√’s 
User-Friendly 
-- √√√√ -- √√√√ 
3 
√’s 
Multi-Functional 
-- -- -- -- 
2 
√’s 
Inexpensive 
-- -- √√ √√ 
1 
√’s 
Storability 
√ √ √ √ 
Totals 14 23 15 14 
As can be seen from the results of Table 4 in the comparative design concept 
matrix, the stent design concept had the highest total result. Thus, this is the design that 
will receive further exploration. 
 
Design Considerations 
While the team and the client identified the conceptual design that would 
accommodate all of the constraints and objectives as seen in Table 4, additional design 
considerations were made during the design process. Through addressing these other 
design considerations, two new designs began to emerge. In the following sections, the 
four design considerations are discussed, all of which led to the creation of the team’s 
two prototypes. 
Sheath Type: Removable versus Degradable 
The team considered two types of sheaths—removable and degradable. The team decided 
to use a removable sheath because it would allow the hMSCs to be in immediate contact 
with the heart tissue. From literary research, using a biodegradable sheath might require 
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too much time for it to degrade, thereby preventing immediate exposure of the hMSCs to 
the heart wall. Additionally, the presence of a biodegradable sheath over that period of 
time may restrict transportation of nutrients and removal of waste, compromising the 
viability of the hMSCs. 
Assembly Methods 
One of the biggest challenges the team faced was determining how to get the seeded 
microthreads into the sheath was the sheath was created. Two approaches were 
considered including slipping the sheath over the suture needle and cutting the sheath. 
The first approach, called the Sock Method, requires the technician to first cut the sheath 
tubing to 3cm in length. The sheath is then slipped over the tip of the needle and then 
progressively moved the sheath down the needle and over the seeded microthreads. The 
second approach, also known as the Cut-Down Method, requires two technicians, a 
surgical scalpel blade, and two pairs of tweezers. After a piece of the sheath tubing was 
cut to a length of 3cm, one end was inserted onto one of the tweezer prongs. Carefully 
using the scalpel, the tubing was cut all the way along one side of the sheath keeping the 
cut as straight as possible. Using the both technicians and both sets of tweezers, the cut 
tubing was held open, while the seeded microthreads were placed inside. By releasing the 
tubing, the sheath closed around the microthreads. 
Needle Attachment Methods 
Another challenge the team had to overcome was how to attach the size 20 curved 
suture needles to the designed protective sheath. Several options were explored including 
the incorporation of a pressure-fitted sheath, utilizing a draw-string created from surgical 
sutures, Krazy Glue, and heat. 
 The team explored the use of two different pressure fittings to secure the needle to 
the sheath. As can be seen in Figures 10 and 11, a barbed and a wedge fit were 
considered. 
 
Figure 10: Barbed Pressure Fit 
 
  Figure 11: Wedge Pressure Fit 
 The drawstring needle attachment method incorporated the use of a surgical 
suture needle to simply tie the curved suture needle to the protective sheath. The curved 
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suture needle is inserted into the sheath, and a suture is tied around the sheath and the 
needle.  
The use of Krazy Glue was also considered, which when sterilized, is more often 
known as Dermabond within the medical community. The active ingredient, 2-octyl 
cyanoacrylate, is responsible for the glue’s immense adhesive abilities. After inserting the 
eye of the curved suture needle into the sheath and holding it with a pair of tweezers, 5μL 
of the glue was pipetted onto the needle-sheath interface. The assembly was held within 
the tweezers for approximately one minute and then left to dry. 
 Lastly, the team explored the possibility of using heat to melt the sheath to the 
needle. When experimenting with the heat attachment method, the team was careful to 
move the sheath far up along the suture needle so as not to accidentally burn the cells or 
the microthreads contained within the sheath. 
 These design considerations resulted in the creation of two sheath prototypes—
one made from polyethylene teraphthalate (PET) and one from polytetrafluoroethylene 
(PTFE). The details of these two designs are described in the next chapter. 
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Two Prototype Designs 
The team developed two final designs that encompassed the most favorable 
features of the conceptual designs. The first sheath, Design I, was made of PET, while the 
second sheath, Design II, was made of PTFE. Each design had its advantages and 
disadvantages, and in this section, both designs are further explained in detail. 
 
Design I: PET Sheath 
 The first design was a removable sheath made of electrospun PET from 
BioSurfaces Incorporated (Ashland, MA) with an inner diameter of 2mm and a length of 
3cm (Figure 12). It was assembled by the Sock Assembly Method as previously 
described, and 1cm of the PET sheath overlapped the base and eye of the needle. Heat 
was applied to attach the sheath to the needle. 
 
Figure 12: Design I (PET Sheath) 
 
Design II: PTFE Sheath 
 The second design was also a removable sheath made from extruded PTFE 
ordered from MocroSoly Technology Corporation (Eatontown, NJ) (Figure 13). The 
inner diameter, however, was 1mm, the outer diameter was 1.58mm, and the length was 
again 3cm. It was assembled through the Cut-Down Assembly Method, and the needle 
was attached to the sheath by applying 5μL of Krazy Glue. The interface was then held 
within the tweezers for approximately one minute and then left to dry. 
 
Figure 13: Design II (PTFE Sheath) 
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Methodology 
This chapter contains the methods by which the materials were tested and chosen, 
in order to create a protective sheath that prevented seeded hMSCs from damage and 
removal during microthread cell delivery to the heart. Furthermore, this chapter shares 
how the device was evaluated and how the results were verified. 
To perform the necessary tests on the two selected sheath designs, one made from 
polyethylene teraphthalate (PET) and one from polytetrafluoroethylene (PTFE), the team 
had to maintain healthy, viable hMSCs throughout the project, as well as produce the 
biological microthreads. Additionally, the cells were seeded on the microthreads using a 
rotational seeding device and quantified to determine seeding efficiency. The team 
performed a uniaxial tensile test on the two sheath designs to determine the failure loads 
for the needle-sheath interfaces. Finally, the sheaths were pulled through the ventricular 
wall of a rat heart to determine whether or not they would successfully protect and 
deliver the cell-seeded microthreads to the area of interest. 
 
Cell Culture 
 A majority of the experiments conducted in this project required the use of 
cultured stem cells. Experiments were performed using passages 5-13 hMSCs cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% Fetal Bovine Serum (FBS) 
and 1% Penicillin/Streptomycin (P/S). To maintain sterility, all cell culture experiments 
were performed aseptically in a biological safety hood. An exact cell culture protocol can 
be viewed in Appendix A. All cells were incubated at 5% CO2 and 37ºC in tissue culture 
treated flasks. 
 
Fibrin Microthread Production 
 Fibrin microthreads were self-assembled from solutions of fibrinogen and 
thrombin. The two solutions were extruded through polyethylene tubing at a pump speed 
of 0.23mL/min into a bath of 10mM HEPES, pH 7.4. Individual threads of less than 
100μm diameter each were produced and bundled into groups of eight with 0.6-0.8mm 
thickness by twisting the microthreads together and allowing them to dry. The exact 
microthread bundling protocol can be viewed in Appendix C and the process can be seen 
in Figure 14. 
 
30 
 
 
Figure 14: Schematic Drawing of Coextrusion System for Producing Self-Assembled Fibrin Microthreads 
 
Microthread Sterilization 
The microthread bundles were assembled by threading the microthreads through 
the eye of the curved suture needle. Once placed within the 1.98mm ID silastic 
bioreactor, slide clamps were placed at each end of the assembly. By using 3mL syringes, 
the microthreads were rehydrated with 100μL of phosphate buffered saline (PBS) for ten 
minutes, sterilized with 300μL of 70% ethanol for thirty-five minutes, and rinsed three 
times with 300μL of sterile deionized water. Using a 3mL syringe, all the sterile 
deionized water was removed, and the microthreads were dynamically seeded within 
thirty minutes. An exact microthread sterilization protocol can be seen in Appendix D. 
 
Dynamic Seeding: Rotational Method 
 Following sterilization, each bioreactor was injected with 100µL of cell 
suspension at a concentration of 100,000cells/100µL using a 1cc syringe and a 27 gauge 
needle. The tubes were placed in 50mL conical tubes (with holes to allow gas exchange) 
and attached to a MACSmix tube rotator at 4rpm. The tubes were placed in an incubator 
at 5% CO2 and 37ºC and rotated for 24 hours. An exact seeding protocol can be seen in 
Appendix E. 
 
Cell Quantification Methods 
Many of the tests that were conducted required the use of cultured hMSCs. To 
detect how many of these hMSCs were successfully delivered and engrafted after 
delivery, several assays were considered to quantify the hMSCs. 
MTS Assay 
The MTS assay is used to measure cell viability and quantity in a living culture. 
The byproducts of living cells react with a tetrazolium compound which results in a 
purple formazen dye. The amount of dye that is present is directly proportional to cell 
metabolic activity and cell quantity. 
After seeding the microthreads, the threads were placed in individual wells in a 
96-well plate. 100µL of media and 20µL of MTS solution were also added to the wells. 
The absorbance of the dye, read at 490nm can be compared to the standard curve of cell 
quantities as demonstrated in Table 5.  
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Table 5: MTS Assay Absorbancies (DiTroia, et al., 2000) 
 
Hoechst Nuclear Stain 
To test cell quantity, the use of a fluorescent dye such as Hoechst nuclear stain 
can be used. By staining the microthreads with the Hoechst dye, the seeded cells can be 
quantified under an optical microscope. The dye binds to the DNA within the cells, which 
when excited at 390nm, will emit a blue light at approximately 490nm. 
To conduct a Hoechst nuclear stain, after seeding the microthreads, they are 
washed in DPBS for 15 minutes. The threads are then fixed using 4% paraformaldehyde 
for 15 minutes. A dilution of 1:6000 Hoechst and DPBS is added, and the solution is let 
to sit for another 15 minutes. Finally the threads are washed in DPBS for 15 minutes. The 
threads are then mounted on glass slides in order to view them under the optical 
microscope.  
Hemocytometer (Fakharzadeh, 2009) 
The last method of cell quantification is the use of a hemocytometer. The media is 
removed from the flask, then 5mL of DPBS is added and the flask is incubated for 5 
minutes. After the 5 minutes, the DPBS is removed and another 5mL of trypsin is added 
to the flask of cells and left to incubate for 5 minutes. After incubation, cell detachment is 
ensured through the use of a microscope. Five mL of media is added, and the mixture is 
transferred to a 15mL conical tube. This tube is centrifuged for 5 minutes at 1,000rpm. 
The media is then aspirated and 0.5mL of media is added. Ten 10µL of the cell mix is 
mixed with 10µL of trypan blue dye in a microcentrifuge tube. A coverslip is placed on 
the hemocytometer and 10µL of the cell/trypan blue solution is added to one square of 
the hemocytometer. This is placed under microscope and the cells are counted in the 
middle square. If 100 cells are observed before counting all five squares, counting may 
cease. However, if less than 100 cells are observed in that first square, counting is 
continued into the other squares. In order to determine the number of cells in the flask 
Equation 1 and Equation 2 were used. 
 
Equation 1: Determining Number of Cells in Flask I 
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Equation 2: Determining Number of Cells in Flask II 
 
 
Mechanical Testing 
 The microthreads, un-seeded and attached to a size 20 suture needle, were placed 
in the Instron machine in order to determine the failure load at the needle-thread 
interface. The assembly underwent a uniaxial tensile test at a rate of 1mm/min to failure. 
The same testing was performed on assemblies with the two sheath designs. The sheaths 
were 3cm long, and the tests provided the load at failure for the sheath-needle interface 
for five trials for each sheath. An exact protocol for the Instron test can be viewed in 
Appendix J. 
 
Proof-of-Concept: Surgery with Both Prototype Designs 
 In order to test the feasibility of our project, the microthreads were sutured 
through the ventricular wall of a paraformaldehyde-fixed rat heart. The same procedure 
was performed with the two sheath designs encompassing the microthreads to determine 
whether or not the sheaths would successfully pass through the heart wall as well as 
protect the threads during suturing. 
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Results  
Each design was subjected to mechanical testing and a proof-of-concept test 
involving suturing it through the heart. The mechanical testing of the PTFE sheath 
resulted in a failure load of 4.25 ± 3.16N (Table 7) while the PET sheath had a failure 
load of 2.58 ± 0.50N (Table 6).  
      
Figure 15: PTFE Sheath                  Figure 16: PET Sheath 
 
Table 6: PET Sheath Failure Loads 
Test # Load at Yield 
1 2.29 N 
2 3.31 N 
3 2.72 N 
4 1.97 N 
5 2.59 N 
Average 2.58 ± 0.502 N 
 
Table 7: PTFE Sheath Failure Loads 
Test # Load at Yield 
1 8.21 N 
2 1.11 N 
4 1.04 N 
5 4.73 N 
6 6.17 N 
Average 4.26 ± 3.16 N 
Based on previous research, the failure load of the actual microthread bundle was 
between 0.13-0.14N. Thus, the team was able to develop a factor of safety of 30 and 18 
for the PTFE and PET sheaths, respectfully. The PTFE was unable to pass through the 
heart (Figure 15), despite it having a higher load at failure yield strength of 4.25N. The 
electrospun PET sheath however, did successfully pass through the heart (Figure 16).  
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Discussion: Design Verification 
Lastly, the PET sheath could be attached to the needle through the use of heat. 
This process was extremely simple to perform, inexpensive, and took less than five 
seconds. By melting the sheath to the needle, a smooth interface was created as well as a 
very strong attachment (as is demonstrated by the Instron results). The PTFE sheath, 
however, could not be melted to the needle and required the use of Krazy Glue. This was 
a complicated, messy, and time-consuming process. 
After the team assembled the PET and PTFE sheaths, obtained their load at failure 
strengths, and conducted a proof-of-concept test in a paraformaldehyde fixed rat heart, it 
was clear which design would best address the needs of the revised client statement. The 
team decided to pursue working with Design I: The PET Sheath for several different 
reasons. 
Electospun PET has many desirable properties for use in cardiac applications in 
comparison to PTFE. PET is an appropriate and biocompatible material for suturing 
through the heart. The PET sheath can be custom-made through the process of 
electrospinning. This allows the sheath to be customized to the sizes necessary depending 
on the patient. Furthermore, electrospinning the PET allows for the sheath to be 
extremely flexible and porous. This is advantageous because it allows for oxygen 
diffusion during incubation in a bioreactor. The PTFE sheath, however, requires 
extrusion equipment to create it, and it must be ordered online where it is available only 
in predetermined sizes and thicknesses. 
 Additionally, the ease of assembly at which the PET sheath can be constructed 
was yet another reason the team decided to use the PET sheath design. The assembly of 
the PET sheath proved much easier than assembling the PTFE sheath. The PET sheath 
required only one technician, whereas the PTFE sheath required two technicians to hold 
the sheath open when inserting the seeded microthreads. Furthermore, the PET sheath 
was flexible and easy to handle, while the PTFE sheath was extremely inflexible and 
slippery due to its high coefficient of friction.  
 Another reason the PET sheath design was further pursued was because of the 
mode of needle attachment. This was done through the use of heat, a process which was 
extremely simple to perform, inexpensive, and required less than five seconds. By 
melting the sheath to the needle, a smooth interface was created as well as a very strong 
attachment (as is demonstrated by the Instron results). The PTFE sheath, however, could 
not be melted to the needle and required the use of Krazy Glue. This was a complicated, 
messy, and time-consuming process. Controlling the placement of the glue was difficult 
due to the capillary action in the PTFE sheath and often, the glue travelled so far down 
the sheath, it made contact with the seeded microthreads. Because the drying time of the 
glue was unknown, incomplete bonding between the needle and the sheath occurred 
several times making experimentation complicated.  
 After determining which material, assembly method, and needle attachment 
strategy would work best for delivering hMSCs to infarcted regions of the heart, the team 
was finally able to conduct two more tests to further validate the PET sheath design. The 
first test involved the use of the Instron uniaxial testing machine to determine the failure 
loads of the PET sheath and the PTFE sheath at their needle-sheath interfaces. Despite 
the fact that the PTFE sheath had a higher mean failure load than the PET sheath at 4.26N 
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and 2.58N, respectively, this was not indicative that the PTFE sheath was necessarily 
better for surgery through a heart wall. Additionally, the PTFE sheath also had a higher 
standard deviation (with n=5) than the PET sheath at ±3.16N and ±0.502N, respectively. 
This suggests that the bonding of the glue to the PTFE sheath was inconsistent, resulting 
in some sheaths with very high failure loads while others had very low failure loads. The 
PET sheath, with a much lower standard deviation, indicates that the strength of the PET 
sheath was consistent from sheath to sheath resulting in it being more reliable.  
The proof-of-concept test further validated why the electospun PET sheath met 
the team’s goals and objectives. Only the PET sheath was able to pass through the stiff 
paraformaldehyde fixed rat heart. This was due to the PET sheath’s soft and flexible 
nature in combination with its smooth needle-sheath interface, resulting in low amounts 
of friction and shear stresses during surgery. Conversely, the PTFE sheath did not 
successfully pass through the heart. This was attributed to the large, rigid, and uneven 
interface between the PTFE sheath and the suture needle, consequently requiring much 
more force to suture through the heart. 
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Conclusions 
Based on the results of these tests, the team determined that the PET sheath was the 
best design to protect the cell-loaded microthread bundles during delivery through the 
heart wall (Figure 17). The sheath was removable so that the hMSCs would be directly 
exposed to the myocytes. It was made out of electrospun PET to allow oxygen diffusion 
as well as flexibility when being sutured through the heart wall. The sock method 
provided ease of assembly. Heat was applied to attach the sheath to the needle to form a 
close, firm, smooth interface. Finally, it was 3cm in length and had a 2mm  inner 
diameter to fully encompass the microthreads. 
 
Figure 17: PET Sheath Final Design 
With these attributes, we believe that the presence of our protective sheath will in 
turn increase the engraftment rate as well as evenly distribute the hMSCs to the area of 
interest, therefore improving cardiac function.
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Regulations and Ethical Issues 
When designing a device to be used in an animal, it is necessary to acknowledge 
that the device must be carefully studied and examined before it can be used on that 
animal. The primary concern is the safety of the animal—for this particular design, a rat. 
In all of the conceptual designs, the safety of the rat was considered; thus all of the 
conceptual designs and the two prototype sheaths were created with an inner diameter of 
2mm. This consideration minimized the damage to the rat’s heart wall during surgery. 
Furthermore the sheaths were made to accommodate a size 20 curved suture needle, 
which is the standard size for suturing microthreads through the ventricle of a rat. 
Additionally, the Institutional Animal Care and Use Committee’s (IACUC) guidelines for 
ethical conduct in the care and use of animals in research were referenced (Gaudette, 
2008).  
 Before the mass production of the final PET sheath design, it would first need to 
be tested on multiple rats to determine and to explore potentially unforeseen problems. It 
is necessary to determine at what point the device is safe enough to use on a rat and when 
the risk of damage is warranted by the benefits of the test. Through contact with IACUC, 
the device could be reviewed as well as the proposed animal testing procedures to 
determine if testing is educationally necessary and receive approval. 
 Whenever any medical device is created, it must meet certain regulatory standards 
in order for it to go to market for use in public practice. The Food and Drug 
Administration (FDA) regulates all medical devices. While the FDA does not extensively 
concern itself with animal regulations, the sheath itself could eventually be used in 
human applications. Therefore, it would need approval from the FDA. It would most 
likely be classified as a Class III device since the safety of the device cannot be assured 
simply by general controls and invasive surgery is required for use. 
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Future Recommendations 
While the proof-of-concept experiments proved helpful in determining which 
prototype design worked best in an actual surgical setting, additional experiments and 
testing should be completed to further improve the PET sheath design. 
 One future recommendation would be to use a PET sheath with an inner diameter 
of 1mm. In the team’s experiments, the sheath had a diameter of 2mm, which is not ideal 
for suturing through a rat heart. However, the ability of PET to be electrospun makes it 
easy to create sheaths of varying diameters to accommodate different patients. 
 A second future recommendation would be to perform cell quantifications 
numerically determine if the sheath is successful at delivery the hMSCs to the infarcted 
region of the heart. Following the sterilization protocol (Appendix D) the team would 
sterilize several bioreactor assemblies, each containing one bundle of eight fibrin and 
four collagen microthreads and a size 20 curved suture needle. Once completely 
sterilized, each of the assemblies would be seeded with hMSCs (Appendix E) using the 
previously stated equations to determine the amount of cells applied. Once seeded in the 
dynamic rotational seeding device for twenty-four hours, the team would remove the 
assemblies from the rotational seeding device. Two bundles of microthreads would be 
removed from their bioreactors and threaded through the bottom left ventricle of a live 
Sprague-Dawney female rat heart and pulled through the epicardium and immediately 
removed through the top of the left ventricle. After removing the microthreads from the 
heart, the team would count the number of cells still remaining on the threads using the 
hemocytometer method (Appendix A). This would provide the team with a baseline cell 
count to which the other two threading experiments would be compared.  
The second two threading experiments would include threading several more 
fibrin-collagen microthread bundles through the rat’s left ventricle; bundles would be 
contained within the PTFE center cut design, while the other bundles would be contained 
within the PTFE wedge with electrospun PET. After the assemblies are threaded 
completely through and removed from the ventricle, the team would again use the 
hemocytometer method (Appendix A) to count the number of cells. The baseline cell 
count, obtained without any protective sheath, could be compared to the cell counts of the 
experiments with the protective sheaths to determine whether the sheaths were effective 
in protecting and delivering the hMSCs. 
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Appendices 
The following section contains supplemental information to what is contained in the 
report. 
 
Appendix A: Cell Culture Protocol (Fakharzadeh, 2009) 
Materials 
- STERILE media: DMEM (Dulbecco’s Modified Eagle’s Medium) with 10% FBS 
 Fetal Bovine Serum) and 1% P/S (Penicillin and Streptomycin)  
- STERILE DPBS (Dulbecco’s Phosphate Buffered Saline), 1X 
- Trypsin EDTA, 1X 
- 10 μL, 100 μL, and 1000 μL pipettes 
- Pipette boy 
- STERILE 10 μL, 100 μL, and 1000 μL pipette tips 
- STERILE T75 or T25 cell culture flask 
- STERILE Pasteur pipettes 
- STERILE serological pipettes 
- STERILE 15 mL conical tube 
- Trypan blue solution in PBS (50% trypan blue solution, 50% PBS) 
- 0.7 mL microcentrifuge tube 
- Hemocytometer 
Procedure 
1. Look at cells under microscope to ensure at least 80% confluency 
2. Remove media from flask 
3. Add 5mL DPBS to flask 
4. Incubate for 5 minutes in hood 
5. Remove DPBS from flask 
6. Add 5mL trypsin to flask 
7. Incubate for 5 minutes in incubator 
8. Look at flask under inverted microscope to ensure cell detachment 
9. Add 5mL media to flask and transfer cell suspension to 15mL conical tube 
10. Centrifuge cell suspension at 1000 RPM for 5 minutes (don’t forget counter 
 weight) 
11. Prepare hemocytometer and allow it to dry 
12. Aspirate supernatant (everything except cell pellet at bottom of conical tube) 
13. Add 0.5mL of media (make sure to mix solution) 
14. Add 10μL of cell suspension to 10μL of trypan blue solution in 0.7mL 
 microcentrifuge tube 
15. Put coverslip on hemocytometer and add 10μL of combined trypan blue 
 solution/cell suspension to one square  
16. Count cells with microscope starting on the middle square segment.  
17. Count cells in the 5 squares. If you reach 100 cells counted before counting all 5 
 squares you may stop counting. Make sure you count all of the cells in 
 each square you choose to count (don’t stop half way!) 
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18. If you do not count 100 cells in the 5 squares you must add the remainder of the 
 trypan blue solution/cell suspension to the other square on the 
 hemocytometer 
19. Repeat step 16 if you need to count more squares 
20. Use the following equation to determine the number of cells in your flask: 
 
 
21. If seeding is desired, use the following equation to determine the required total 
 volume of cell suspension: 
 
So, for example when I seed my microthreads I need a volume of 100μL per seeding 
tube and I want 100,000 cells in that 100μL of cell suspension. So I would plug the 
following values into this equation, assuming that I have 500,000 cells: 
 
For this example Y would equal 500μL. Since I already added 500μL to the cells after 
centrifugation I don’t need to add any more media in this case. So whenever you start 
with a cell suspension of 500μL, you need to subtract that from the Y value you 
solved for  
(Y – 500).  
22. If only subculture is desired, use the equation above to make a cell concentration 
 of  
23. After seeding or when subculturing the remaining cell suspension must be 
 transferred into either  T75 or T25 flasks. 500,000 cells should be put into 
 a T75 flask and 160,000 cells should be put into a T25 flask to ensure 
 proper growth 
24. After cells suspension has been added to the appropriate size flask(s) calculate the 
 amount of media that you must add to create a total volume of 10mL for 
 T75 flasks or 3mL for T25 flasks. 
25. Put cells back in incubator and feed them the NEXT DAY 
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Appendix B: Cell Feeding Protocol (Fakharzadeh, 2009) 
Materials 
- Gloves 
- DMEM media (10% FBS and 1% PIS) 
- Container of Pasteur Pipettes 
- 10mL surgical pipette 
Procedure 
1. Place the DMEM into the water bath until it reaches 37*C (can aliquot this out in 
 order to decrease the heating time) 
2. Spray hood, tools, and vacuum tube with EtOH 
3. Touching only one Pasteur pipette at a time, remove one from the container and 
 attach it to the  vacuum tube 
4. Retrieve the cells from the incubator and check them in the microscope for 
 contamination 
5. Retrieve the DMEM from the water bath and wipe it down with EtOH 
6. Wipe gloves with EtOH 
7. Using the vacuum with the attached Pasteur pipette, suck the old DMEM media 
 up from the cells 
8. Using the surgical pipettes, place 3mL of the heated DMEM into the container 
holding the cells 
9. Surgical pipette goes in the biohazard waste 
10. Pasteur pipette goes in the sharps container 
11. Wipe down everything with EtOH 
* TO AVOID CONTAMINATION, DO NOT PASS HAND OVER ANYTHING! 
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Appendix C: Microthread Bundling Protocol (Fakharzadeh, 2009) 
Materials 
- Gloves 
- Overhead projector screen 
- Black mat 
- 2 pairs of forceps 
- 2 pieces of tape 
- DI H20 
- Fibrin threads 
- Needle 
- Scissors 
Procedure 
1. Lay 8 fibrin threads of the same length on the overhead projector screen as close 
 as possible 
2. Push the 8 ends as close as possible and tape them down on the overhead 
 projector 
3. Note: we have no need for the collagen threads because we will have the sheath to 
 protect them therefore, we don’t need the added stability/strength 
 associated with the collagen threads 
4. With your dominant hand at the tape end and your non-dominant hand holding the 
 threads taught, smooth the DI H2O along the threads using a plastic pipette 
5. Place a kimwipe underneath the threads so they don’t stick to the projector screen 
6. Cut the threads at the un-taped end so they are all the same exact length 
7. Let the threads dry 
8. Measure 4cm of the threads starting from the un-taped end and cut the threads 
9. Pass the threads through the needle using the forceps 
10. Wrap the two halves of the thread bundle around itself 
11. Wet the threads using lots of DI H2O 
12. Twist both strands together and rewet 
13. Let the bundle dry 
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Appendix D: Microthread Sterilization Protocol (Fakharzadeh, 2009) 
Materials 
- PBS (phosphate buffered saline) 
- 70% ethanol 
- STERILE DI (deionized) water 
- STERILE 3 mL syringes 
- Tissue culture dish 
- Prepared microthreads 
Procedure 
1. Remove side clamp and add 100 μL PBS with 3 mL syringe to each microthread 
 bundle 
2. Replace side clamp 
3. Allow to hydrate for 10 minutes 
4. Remove side clamp and add 300 μL of 70% ethanol with new 3 mL syringe to 
 each microthread bundle to ensure that all PBS has been removed 
5. Replace side clamp 
6. Allow to sterilize for 35 minutes 
7. Remove side clamp and add 300 μL of STERILE DI water with new 3 mL 
 syringe to each microthread bundle to ensure that all ethanol has been 
 removed 
8. Replace side clamp 
9. Allow to hydrate for 10 minutes 
10. Repeat steps 7-9 two more times 
11. Use new 3 mL syringe to remove all DI water 
12. Seed microthreads within 30 minutes 
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Appendix E: Microthread Seeding Protocol (Fakharzadeh, 2009) 
Materials 
- 1.98 mm I.D. Silastic tubing 
- (2) side clamps  
- Size 18 half circle tapered suture needle 
- Biological microthread bundle (collagen/biodegradable microthreads) 
- PBS 
- Sterile PBS 
- 70% Ethanol 
- (6) sterile syringes 
- 27G needle (without sharp tip) 
- Sterile 1 cc syringe 
- Cell suspension (100,000 cells/100 μL) 
- 50 mL conical tube  
Procedure 
1. Use a new syringe to expel all sterile PBS from the bioreactor immediately before 
seeding  
2. Use a new syringe (1 cc maximum) to inject 100 μL of cell suspension (my cell 
concentration is 100,000 cells/100 μL) into the bioreactor  
3. After seeding, remove 27G needle from bioreactor 
4. Place bioreactor in 50 mL conical tube 
5. Place bioreactor in MACSmix tube rotator and rotate at 4 RPM (lowest setting) 
for 24 hours 
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Appendix F: Design Team’s Pairwise Comparison Chart 
 
Pairwise Comparison Chart for Main Objectives 
 
User-
friendly 
Compatible Inexpensive Storability 
Degradable/easily 
removable 
Multi-
functional 
Mechanical 
integrity/durability 
Total 
User-friendly x 0 1 1 0.5 1 0.5 4 
Compatible 1 x 1 1 1 1 1 6 
Inexpensive 0 0 x 1 0 1 0 2 
Storability 0 0 0 x 0 1 0 1 
Degradable/easily 
removable 
0.5 0 1 1 x 1 0.5 4 
Multi-functional 0 0 0 0 0 x 0 0 
Mechanical 
integrity/durability 
0.5 0 1 1 0.5 1 x 4 
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Appendix G: Client’s Pairwise Comparison Chart 
 
Pairwise Comparison Chart for Main Objectives 
 
User-
friendly 
Compatible Inexpensive Storability 
Degradable/easily 
removable 
Multi-
functional 
Mechanical 
integrity/durability 
Total 
User-friendly X 0 1 1 1 0 0 3 
Compatible 1 x 1 1 0.5 1 1 5.5 
Inexpensive 0 0 x 1 0 0 0 1 
Storability 0 0 0 X 0 0 0 0 
Degradable/easily 
removable 
0 0.5 1 1 X 1 0 3.5 
Multi-functional 1 0 1 1 0 X 0 3 
Mechanical 
integrity/durability 
1 0 1 1 1 1 X 5 
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Appendix H: User’s Pairwise Comparison Chart 
 
Pairwise Comparison Chart for Main Objectives 
 
User-
friendly 
Compatible Inexpensive Storability 
Degradable/easily 
removable 
Multi-
functional 
Mechanical 
integrity/durability 
Total 
User-friendly X 0.5 1 1 0.5 0 0.5 3.5 
Compatible 0.5 X 1 1 0.5 1 1 4.5 
Inexpensive 0 0 X 1 0 0 0 1 
Storability 0 0 0 X 0 0 0 0 
Degradable/easily 
removable 
0.5 0.5 1 1 X 1 0.5 3.5 
Multi-functional 1 0 1 1 0 X 0.5 3.5 
Mechanical 
integrity/durability 
0.5 0 1 1 0.5 0.5 X 3.5 
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Appendix I: Post-Seeding Technique 
1) Remove thread bundle 
2) Place thread bundle in 250mL of dionized water for 5minutes 
3) Place in trypsin (800μL in 1.7mL tube) for 30minutes 
a. Every 5minutes, shake tube to ensure detachment 
4) Add 800μL DMEM (10% FBS, 1%P/S) to inactivate trypsin 
5) Centrifuge at 10,000RPM for 10minutes 
6) Aspirate supernatant with 100μL pipette (leave 10-20μL in tube) 
7) Add 10μL of cell suspension to trypan blue solution and count cells 
a. Confirm how much suspension remains to calculate the number of cells on 
the thread (use 10μL pipette and pipette 5mL at a time until the suspension 
is left) 
b. Count all cells (including blue ones!) 
 
Appendix J: Mechanical Testing Protocol 
1. Switch on Instron machine. 
2. Open the Bluehill 2 Software. 
3. Create new method icon. 
a. Specimen geometry (tubular), OD (1/16in = 0.0625in = 1.5875), wall 
thickness (0.5875mm), length(3cm), final length (predict to 3.5cm), final 
OD (predict to 1.48), final wall thickness (predict to 0.48mm) 
b. Control  Ramp1 control mode 1  Tensile extension and Rate 1  
1mm/min 
c. Control end of test  end of test 1 criteria 1 tensile extension and 
Value 1 5mm 
d. End of test  Calculations  Yield, maximum tensile extension 
e. Results 1  statistics  Mean +SD 
f. Results 1  Load at Yield (zero slope) 
g. Graph 1 Graph title, sample number 
h. Export Results and Raw Data Comma separated values 
i. Reports  choose saving settings 
4. Perform test. 
a. Place sample in grips and tighten to secure. 
b. Bluehill  method  first in list is your method 
c. Bluehill  test  select your test  type sample file name (Example: 
―PTFE 1, 3/3/2010‖) 
d. Next 
e. Zero extension and load 
f. Select start 
g. Stop at breakage 
h. Return button 
i. Save as  keep file type  
j. Finish button  yes 
